Harry Alcorn

Mechmath (United States) — United States

Medicine · Health Sciences

17h-index1.6kcitations39works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antibiotics Pharmacokinetics and Efficacy(8), Pharmaceutical studies and practices(5), Antibiotic Resistance in Bacteria(4), Hepatitis C virus research(3), Antimicrobial Resistance in Staphylococcus(3)

Publications39 total

Abstract 4351158: Pharmacodynamics (PD) of a Subcutaneous (SC) Injection of a Novel-Formulation of furosemide (FUR)
Circulation·2025
Pharmacokinetics and Pharmacodynamics of a Novel Formulation of Furosemide Administered as a Single Subcutaneous Injection
Clinical Therapeutics·2025Open Access
Plasma and Urine Potassium (K+) Changes After Single Subcutaneous (SC) Injection of Novel Formulation of Furosemide (FUR)
Journal of the American Society of Nephrology·2025
REDUX: A Multicenter, Open-Label Study of DM199 (Recombinant Human Tissue Kallikrein-1) in Patients with Stage 2 or 3 CKD
Journal of the American Society of Nephrology·2021
Pharmacokinetics of Gepotidacin in Renal Impairment
Clinical Pharmacology in Drug Development·2020· 16 citedOpen Access
Issue Information
The Journal of Clinical Pharmacology·2018Open Access
Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment
The Journal of Clinical Pharmacology·2018· 35 citedOpen Access
Issue Information
The Journal of Clinical Pharmacology·2018Open Access
Pharmacokinetics of Intravenous Delafloxacin in Patients With End‐Stage Renal Disease
The Journal of Clinical Pharmacology·2018· 16 cited
Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
The Journal of Clinical Pharmacology·2017· 32 citedOpen Access
Special Populations in Clinical Pharmacology Studies: Evolving Challenges
Therapeutic Innovation & Regulatory Science·2017· 1 cited
Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics
European Journal of Clinical Pharmacology·2017· 36 citedOpen Access
Nalbuphine hydrochloride extended release PK in hemodialysis patients and pruritus
Journal of Nephrology & Therapeutics·2016
Rivaroxaban in Chronic Hemodialysis Patients
American Journal of Nephrology·2016· 6 citedOpen Access
Supplementary Material for: Rivaroxaban in Chronic Hemodialysis Patients
Figshare·2016Open Access
Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus
BMC Nephrology·2015· 66 citedOpen Access
Pharmacokinetics and pharmacodynamics of pegloticase in patients with end-stage renal failure receiving hemodialysis
Clinical Nephrology·2015· 9 cited
Single-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a FabI Inhibitor, the Prodrug Debio 1450 and Its Active Moiety Debio 1452, Administered Intravenously in Healthy Subjects
Open Forum Infectious Diseases·2015· 3 citedOpen Access
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Nebulized Sodium Nitrite (AIR001) Following Repeat-Dose Inhalation in Healthy Subjects
Clinical Pharmacokinetics·2014· 47 citedOpen Access
The Effect of Renal Impairment on Single-Dose Pharmacokinetics of Daclatasvir, an HCV NS5A Inhibitor
The American Journal of Gastroenterology·2014· 5 cited
page 1 of 2Next →

Frequent Co-authors

Thomas Marbury(8), Randall Hoover(5), Laura Lawrence(5), Susan K. Paulson(5), Megan Quintas(5), Sue Cammarata(5), Jolene Kay Berg(3), John Mohr(3), Barbara Cornelius(3), Kamyar Kalantar‐Zadeh(2), Ryan D. Kilpatrick(2), Noriko Kuwae(2), Charles J. McAllister(2), Joel D. Kopple(2), Sander Greenland(2), Shawn D. Flanagan(2), Denise Morris(2), Edward Fang(2), Philippe Prokocimer(2), Τushar Garimella(2)